Tanya Dorff, MD
While progress has been made in the management of metastatic castration-resistant prostate cancer (mCRPC) with the addition of targeted therapies to the armamentarium, there are still several unresolved issues, according to Tanya B. Dorff, MD.
on Genitourinary Cancers, Dorff, an associate professor of clinical medicine at University of Southern California, discussed several important components regarding mCRPC treatment, including the addition of novel drugs, optimal therapeutic sequences, and the identification of predictive biomarkers.
OncLive: What agents do you currently look at when a patient’s disease progresses?
The questions are how to best use the tools we have, which include abiraterone acetate (Zytiga), enzalutamide (Xtandi), docetaxel, cabazitaxel (Jevtana), radium-223 dichloride (Xofigo), and sipuleucel-T (Provenge). It has obviously gotten a bit more complicated as Dr Guru P. Sonpavde said in his talk [during the meeting] about upfront intensification…We would approach the patients with single sequential therapy, and, typically, we might want to use immunotherapy earlier rather than later.
... to read the full story